Sugi Predict

Sugi Predict / Targets / STK36

STK36

Serine/threonine-protein kinase 36 · Q9NRP7 · STK36 on Sugi Atlas →

627 patent compounds predicted against STK36, 523 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4135600 SCHEMBL4135600 0.78 2/20
SCHEMBL2650684 SCHEMBL2650684 0.75 2/20
SCHEMBL6465326 SCHEMBL6465326 0.74 2/20
SCHEMBL4553131 SCHEMBL4553131 0.70 2/20
SCHEMBL7231228 SCHEMBL7231228 0.70 2/20
SCHEMBL2648503 SCHEMBL2648503 0.70 2/20
SCHEMBL2649542 SCHEMBL2649542 0.70 2/20
SCHEMBL4551864 SCHEMBL4551864 0.70 2/20
SCHEMBL7249555 SCHEMBL7249555 0.70 2/20
SCHEMBL19857269 SCHEMBL19857269 0.70 2/20
SCHEMBL21169981 SCHEMBL21169981 0.70 2/20
SCHEMBL2650680 SCHEMBL2650680 0.66 2/20
SCHEMBL13497841 SCHEMBL13497841 0.65 2/20
SCHEMBL19857273 SCHEMBL19857273 0.65 2/20
SCHEMBL8486792 SCHEMBL8486792 0.62 2/20
SCHEMBL9196324 SCHEMBL9196324 0.61 2/20
SCHEMBL69095 SCHEMBL69095 0.60 2/20
SCHEMBL8490670 SCHEMBL8490670 0.60 2/20
SCHEMBL67376 SCHEMBL67376 0.58 2/20
SCHEMBL13497913 SCHEMBL13497913 0.58 2/20

Clinical trials — most relevant to STK36 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease PHASE2COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors PHASE1/PHASE2NOT_YET_RECRUITING
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). PHASE1ACTIVE_NOT_RECRUITING
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. PHASE1ACTIVE_NOT_RECRUITING
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a STK36 binder may also engage these)

ProteinNameSimilarity
Q5RAJ5 — 1.000 Q5RAJ5 →
Q69ZM6 — 1.000 Q69ZM6 →
Q2LGB3 — 0.989 Q2LGB3 →
Q3UJB9 — 0.989 Q3UJB9 →
Q5R810 — 0.988 Q5R810 →
Q8K330 — 0.988 Q8K330 →
Q5BIW4 — 0.988 Q5BIW4 →
A1L3T7 — 0.988 A1L3T7 →
Q3UIZ8 — 0.987 Q3UIZ8 →
Q15345 — 0.987 Q15345 →
Q9EQR6 — 0.986 Q9EQR6 →
Q8R2S1 — 0.986 Q8R2S1 →
O35870 — 0.986 O35870 →
IRAK2 Interleukin-1 receptor-associated kinase-like 2 0.986 landscape →
Q3UHQ6 — 0.985 Q3UHQ6 →
Q8K1C9 — 0.985 Q8K1C9 →
D2I4M3 — 0.984 D2I4M3 →
Q1MX18 — 0.984 Q1MX18 →
Q5TIA1 — 0.984 Q5TIA1 →
Q7Z3H0 — 0.984 Q7Z3H0 →
Q3ULW6 — 0.983 Q3ULW6 →
A1YER0 — 0.983 A1YER0 →
A8C756 — 0.983 A8C756 →
P0C5Y8 — 0.983 P0C5Y8 →
Q96MK2 — 0.983 Q96MK2 →
Q8VDP4 — 0.983 Q8VDP4 →
Q6TXD4 — 0.983 Q6TXD4 →
Q75NR7 — 0.983 Q75NR7 →
Q0P5I2 — 0.983 Q0P5I2 →
Q60670 — 0.983 Q60670 →